All In MedTech

Device Trial Radar · NCT05782556

Freiburg TIPS Registry

Transjugular Intrahepatic Portosystemic Shunt (TIPS) for the Treatment of Portal Hypertension: an Observational Study

Last checked: Nov 20, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

2,000

Planned (sponsor's estimate)

Start

Jan 1, 2023

Primary completion

Dec 31, 2033

Study completion Jun 30, 2034

Sponsor

Lead sponsor
University Hospital FreiburgAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 23, 2023

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with clinically significant portal hypertension allocated to implantation of a transjugular intrahepatic portosystemic shunt (TIPS) at the Department of Medicine II of the University Medical Center Freiburg, Germany will be offered to participate in this prospective observational trial. Clinical and laboratory as well as outcome parameters will be assessed before and within the first 12 months after TIPS implantation following a regular follow-up schedule with clinical visits at the University Medical Center Freiburg. During follow-up visits, serum/plasma samples and peripheral blood mononuclear cells (PBMC) are collected and stored in a associated biobank.

Conditions

  • Liver Cirrhosis
  • Portal Hypertension
  • Non-Cirrhotic Portal Hypertension
  • Budd Chiari Syndrome
  • Portal Vein Thrombosis
  • Portal Systemic Shunt

Interventions

  • Implantation of a transjugular intrahepatic portosystemic shunt (TIPS)Device

    For TIPS implantation, a transjugular approach is used in all patients and a puncture needle was advanced into a hepatic vein. Puncture of the portal vein is performed using ultrasound guidance followed by portography after successful puncture of the portal vein. Further, the parenchymal tract isdilated and the stent graft is placed. Before and after TIPS implantation, portal venous and central venous pressures are measured to calculate the porto-systemic pressure gradient

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Transplantation-free survivalTime frame: 01/01/2023-31/12/2033

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Medical Center Freiburg, Department of Medicine II

    Freiburg im Breisgau, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.